Seelaus Asset Management’s Calithera Biosciences, Inc CALA Stock Holding History

Seelaus Asset Management’s Portfolio CALA Stock Details CALA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-820	Closed	-$7K	–	293
2022 Q1	$7K	Hold	820	–	–	﹤0.01%	273
2021 Q4	$11K	Buy	820 +12	+1%	+$302	0.01%	274
2021 Q3	$35K	Hold	808	–	–	0.02%	250
2021 Q2	$34K	Buy	808 +150	+23%	+$6.59K	0.02%	248
2021 Q1	$32K	Hold	658	–	–	0.02%	213
2020 Q4	$65K	Hold	658	–	–	0.05%	192
2020 Q3	$45K	Hold	658	–	–	0.04%	160
2020 Q2	$69K	Buy	+658	New	+$78.2K	0.06%	139
2019 Q4	–	Sell	-508	Closed	-$31K	–	180
2019 Q3	$31K	Buy	+508	New	+$40.7K	0.03%	160

Other funds holding CALA

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCMG

TSP Capital Management Group Summit, New Jersey $410M AUM 71.81% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Seelaus Asset Management's CALA Position: Q2 2022 in Review

Seelaus Asset Management sold out of Calithera Biosciences, Inc (CALA) in Q2 2022, closing a stake of 820 shares — an estimated $7K sold.

Seelaus Asset Management first reported a position in CALA in Q3 2019 and held it in 9 quarters. The position peaked at $69K in Q2 2020. 28 funds tracked by Wall St. Rank hold CALA as of Q2 2022.

Seelaus Asset Management reported no remaining Calithera Biosciences, Inc position as of Q2 2022 after selling out during the quarter.
Seelaus Asset Management sold 820 Calithera Biosciences, Inc shares in Q2 2022, an estimated $7K.
Seelaus Asset Management first reported a position in Calithera Biosciences, Inc in Q3 2019 and held it in 9 quarters.
Seelaus Asset Management's Calithera Biosciences, Inc position peaked at $69K in Q2 2020.
28 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q2 2022.

Based on Seelaus Asset Management's 13F filing for Q2 2022, filed 5 Aug 2022.